Global Induced Pluripotent Stem Cells (iPSCs) Market Size, Status and Forecast 2022

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.
The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.

Market Analysis and Insights: Global Induced Pluripotent Stem Cells (iPSCs) Market
The global Induced Pluripotent Stem Cells (iPSCs) market size is projected to reach US$ 203.6 million by 2027, from US$ 90 million in 2020, at a CAGR of 12.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Induced Pluripotent Stem Cells (iPSCs) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Induced Pluripotent Stem Cells (iPSCs) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Induced Pluripotent Stem Cells (iPSCs) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Induced Pluripotent Stem Cells (iPSCs) market.

Global Induced Pluripotent Stem Cells (iPSCs) Scope and Market Size
Induced Pluripotent Stem Cells (iPSCs) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Induced Pluripotent Stem Cells (iPSCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Human iPSCs
Mouse iPSCs

Segment by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL